Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.46 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17810160 | 0.82 | MMP1 (0.49) | MAOBPTPN1PTPRCPTPN2PTPRB | |
| SCHEMBL10104014 | 0.81 | MAOB (0.58) | MAOBMAOA | |
| SCHEMBL18164548 | 0.79 | MAOB (0.70) | MAOBIDO1PTPN1PTPRCPTPN2 | |
| SCHEMBL9747473 | 0.79 | MAOB (0.49) | MAOBARMAOA | |
| SCHEMBL2873573 | 0.79 | MAOB (0.69) | MAOBIDO1PTPN1PTPRCPTPN2 | |
| Ammonia Solution, Strong SCHEMBL6903652 | 0.77 | MAOB (0.67) | MAOBIDO1PTPN1PTPRCPTPN2 | |
| SCHEMBL2877136 | 0.77 | MAOB (0.58) | MAOBIDO1MAOA | |
| SCHEMBL4883457 | 0.77 | MAOB (0.72) | MAOBPTPN1PTPRCPTPN2PTPRB | |
| SCHEMBL11426612 | 0.77 | MAOB (0.67) | MAOBIDO1PTPN1PTPRCPTPN2 | |
| SCHEMBL557817 | 0.77 | LMNA (0.57) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9365540-B2 | Benzimidazole derivatives as MCH receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9296743-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2476680-B1 | (1-Azinone)-Substituted Pyridoindoles | ALBANY MOLECULAR RES INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716308-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2476680-A1 | (1-Azinone)-Substituted Pyridoindoles | Albany Molecular Research, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2240481-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | Albany Molecular Research, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | MAOB 1038/4885IDO1 3586/4885PTPN1 1601/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MAOB 1090/4885IDO1 3764/4885PTPN1 1858/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | MAOB 1038/4885IDO1 3586/4885PTPN1 1601/4885 |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MAOB 1090/4885IDO1 3764/4885PTPN1 1858/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MAOB 1090/4885IDO1 3764/4885PTPN1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.